A new generics company merging Mylan (Nasdaq: MYL) with Pfizer’s (NYSE: PFE) Upjohn will be named Viatris, the firms have announced.
Pfizer’s off-patent unit Upjohn, which distributes aging staples such as Lipitor (atorvastatin) and Viagra (sildenafil), will sit alongside Mylan’s range of newer generics and biosimilars.
Upjohn has a strong position in China and emerging markets, while Mylan has developed a significant presence in the USA and in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze